Adalimumab is a biologic medication used to treat several inflammatory conditions by blocking tumor necrosis factor alpha. Although it can help reduce inflammation, it may also increase susceptibility to certain infections by affecting immune system activity. Understanding infection prevention is important for people receiving this treatment. Appropriate hygiene, vaccination guidance, regular medical monitoring.
Adalimumab is a tumor necrosis factor (TNF) inhibitor prescribed for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, and ulcerative colitis. TNF plays an important role in inflammation and immune responses. By blocking this protein, adalimumab helps control inflammatory activity, but it can also reduce the body's ability to fight certain infections.
People receiving adalimumab may have an increased risk of bacterial, fungal, and viral infections. Some infections can become serious, particularly in individuals with additional health conditions or other medications that suppress the immune system.
Common infection prevention considerations include:
Tuberculosis screening: Healthcare professionals generally evaluate patients for active and latent tuberculosis before treatment. Additional monitoring may be necessary if exposure occurs during therapy.
Hygiene practices: Regular handwashing, appropriate food handling, and avoiding close contact with people who have contagious illnesses can help reduce exposure to infectious organisms.
Vaccination guidance: Patients should discuss recommended vaccines with their healthcare professionals before and during treatment. Live vaccines are generally avoided during adalimumab therapy because of the potential risk of infection.
Medical history review: Patients should disclose previous serious infections, recurrent infections, hepatitis B infection, and other relevant medical conditions before starting treatment.
Infection prevention continues throughout treatment, not only before the first dose. Regular medical appointments help healthcare professionals assess treatment response, review possible adverse effects, and identify concerns that may require further evaluation. Patients should report new symptoms promptly rather than assuming they are minor or unrelated to their medication.
Practical precautions and appropriate communication with healthcare professionals can help individuals recognize potential problems early.
Recognize warning signs: Fever, persistent cough, shortness of breath, unusual fatigue, painful urination, or skin redness and swelling may indicate an infection. Severe or worsening symptoms require prompt medical assessment.
Report possible exposure: Individuals who have been exposed to tuberculosis, chickenpox, shingles, or another significant infection should contact their healthcare professional for advice.
Review other medications: Corticosteroids and other immune-suppressing medicines may increase infection risks when used alongside adalimumab. Patients should discuss all prescribed medicines and supplements with their healthcare team.
Follow medical instructions: If an infection develops, a healthcare professional may recommend testing, treatment, or temporarily withholding adalimumab, depending on its severity. Patients should not independently change their medication schedule.
Maintain follow-up care: Routine consultations allow clinicians to review symptoms, screening needs, and individual risk factors throughout treatment.
Adalimumab can provide meaningful benefits for inflammatory conditions, but its effects on immune function require appropriate precautions. Understanding infection risks, following medical guidance, maintaining recommended preventive practices, and reporting concerning symptoms can support safer treatment. Decisions about vaccinations, screening, and medication adjustments should always be based on individual medical circumstances and professional advice.